These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 33181704)

  • 21. Renal function markers and metformin eligibility.
    Tavares Bello C; Castro Fonseca R; Sousa Santos F; Sequeira Duarte J; Azinheira J; Vasconcelos C
    Minerva Endocrinol; 2018 Sep; 43(3):246-252. PubMed ID: 28565889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
    Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
    Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin doses to ensure efficacy and safety in patients with reduced kidney function.
    Kuan IHS; Wilson LC; Leishman JC; Cosgrove S; Walker RJ; Putt TL; Schollum JBW; Wright DFB
    PLoS One; 2021; 16(2):e0246247. PubMed ID: 33600406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry.
    Radwan MA; Al Taweel ES; Al-Moghairi AM; Aloudah NM; Al Babtain MA; Al-Amri HS
    Ther Drug Monit; 2011 Dec; 33(6):742-9. PubMed ID: 22105592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus.
    Sambol NC; Chiang J; O'Conner M; Liu CY; Lin ET; Goodman AM; Benet LZ; Karam JH
    J Clin Pharmacol; 1996 Nov; 36(11):1012-21. PubMed ID: 8973990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
    Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
    J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
    Hussey EK; Kapur A; O'Connor-Semmes R; Tao W; Rafferty B; Polli JW; James CD; Dobbins RL
    BMC Pharmacol Toxicol; 2013 Apr; 14():25. PubMed ID: 23631443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations.
    Frid A; Sterner GN; Löndahl M; Wiklander C; Cato A; Vinge E; Andersson A
    Diabetes Care; 2010 Jun; 33(6):1291-3. PubMed ID: 20215446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor.
    Marier JF; Mouksassi MS; Gosselin NH; Li J
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):297-304. PubMed ID: 27128836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine.
    Tuot DS; Lin F; Shlipak MG; Grubbs V; Hsu CY; Yee J; Shahinian V; Saran R; Saydah S; Williams DE; Powe NR;
    Diabetes Care; 2015 Nov; 38(11):2059-67. PubMed ID: 26307607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin.
    Warren RE; Strachan MW; Wild S; McKnight JA
    Diabet Med; 2007 May; 24(5):494-7. PubMed ID: 17367305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of metformin in late pregnancy.
    Charles B; Norris R; Xiao X; Hague W
    Ther Drug Monit; 2006 Feb; 28(1):67-72. PubMed ID: 16418696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of serum creatinine and kidney function among incident metformin users.
    Schorr M; Hemmelgarn BR; Tonelli M; Soo A; Manns BJ; Bresee LC;
    Can J Diabetes; 2013 Aug; 37(4):226-230. PubMed ID: 24070885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).
    Weinrauch LA; D'Elia JA; Finn P; Lewis EF; Desai AS; Claggett BL; Cooper ME; McGill JB
    Diabetes Res Clin Pract; 2016 Mar; 113():143-51. PubMed ID: 26830074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.
    Revilla N; Martín-Suárez A; Pérez MP; González FM; Fernández de Gatta Mdel M
    Br J Clin Pharmacol; 2010 Aug; 70(2):201-12. PubMed ID: 20653673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.